July 26, 2012

As expected, Q2 2012 Business EPS1 impacted by the loss of exclusivity of Plavix® and Avapro® in the U.S.

 

As expected, Q2 2012 Business EPS1 impacted by the loss of exclusivity of Plavix® and Avapro® in the U.S.

Commenting on the Group’s performance in Q2 2012, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, “This quarter, we faced the anticipated loss of exclusivity of Plavix® and Avapro® in the U.S. The strategy initiated at the end of 2008 focusing on the development of our growth platforms2, coupled with continuous tight cost control and value-creating acquisitions allowed Sanofi to limit the impact on business EPS1. In addition, we made progress in advancing our pipeline with the submission of LemtradaTM (alemtuzumab)3 to the U.S. and EU regulatory agencies as well as the recent initiation of a comprehensive Phase III program for an Anti-PCSK-9 monoclonal antibody4.